Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23790072 | 0.86 | MEN1 (0.45) | POLBKDM4EMAPTALDH1A1DRD2 | |
| SCHEMBL16316312 | 0.83 | POLB (0.50) | POLBL3MBTL1KDM4EMAPTALDH1A1 | |
| SCHEMBL20806670 | 0.82 | ARG1 (0.33) | KDM4EALDH1A1ARG1ARG2TDP1 | |
| SCHEMBL25971293 | 0.81 | MEN1 (0.49) | POLBKDM4EMAPTALDH1A1CYP1A2 | |
| SCHEMBL25138073 | 0.81 | MEN1 (0.49) | POLBKDM4EMAPTALDH1A1CYP1A2 | |
| SCHEMBL21946773 | 0.81 | MEN1 (0.49) | POLBKDM4EMAPTALDH1A1CYP1A2 | |
| SCHEMBL19914476 | 0.81 | ALDH1A1 (0.56) | POLBALDH1A1ALOX12CA3CA5A | |
| SCHEMBL25880987 | 0.80 | ALDH1A1 (0.41) | POLBKDM4EMAPTALDH1A1CYP1A2 | |
| SCHEMBL13341020 | 0.79 | POLB (0.33) | POLBKDM4EMAPTHDAC6SMN1; SMN2 | |
| SCHEMBL23975224 | 0.79 | POLB (0.40) | POLBKDM4EMAPTALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023004163-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2023287928-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2020150263-A1 | SELECTIN OR GALECTIN ANTAGONISTS FOR TREATING CYTOKINE RELEASE SYNDROME AND CRS-INDUCED NEUROTOXICITY | MAGNANI JOHN L (US) | 2020-07-23 | — | — | WO | disclosed |
| US-6703387-B2 | STYRYLBENZODIAZEPINES | HOFFMANN-LA ROCHE INC. | 2004-03-09 | — | — | US | disclosed |
| EP-1299364-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-09 | — | — | EP | disclosed |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-09-12 | — | — | US | disclosed |
| WO-2002000632-A1 | BENZODIAZEPINES AS INHIBITORS OF HPV E1 HELICASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | POLB 1390/4885L3MBTL1 703/4885GAA 350/4885 |
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | POLB 1827/4885L3MBTL1 857/4885GAA 387/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | POLB 1390/4885L3MBTL1 703/4885GAA 350/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | POLB 3151/4885L3MBTL1 2541/4885GAA 1624/4885 |
| US-20020128262-A1 | Inhibitors of HPV E1 helicase enzyme | DHX15, DHX35, DHX36 | POLB 76/4885L3MBTL1 3950/4885GAA 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.